# Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint

> **NCT05216341** · PHASE2 · COMPLETED · sponsor: **OliPass Corporation** · enrollment: 134 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** OLP-1002

## Key facts

- **NCT ID:** NCT05216341
- **Lead sponsor:** OliPass Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-11
- **Primary completion:** 2023-09-07
- **Final completion:** 2023-09-07
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2024-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05216341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05216341, "Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05216341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*